Ketones, Energy, and Weight

Evidence Review

Brain energy metabolism (PMID 29914035)

Croteau et al. (2018) used PET imaging to directly measure brain uptake of both ketones and glucose in 20 Alzheimer's patients and 20 age-matched controls before and after supplementation with two types of MCT-based ketogenic supplement. Brain ketone consumption approximately doubled with both supplements; brain glucose uptake remained unchanged (impaired). The increase in ketone utilization was proportional to plasma ketone concentrations achieved. The study was well-controlled with repeated measures and objective imaging endpoints, making it one of the strongest mechanistic demonstrations that MCT-derived ketones can partially compensate for brain glucose deficits in Alzheimer's disease.

A 2019 systematic review (PMID 31870908) synthesized available RCT data in MCI/AD populations and found that MCTs consistently induced mild ketosis (blood BHB ~0.3-0.5 mmol/L) and were associated with improved performance on combined cognitive measures in meta-analysis. The authors described the meta-analysis as highly homogeneous, supporting a real — if modest — effect.

Weight and body composition (PMIDs 25636220, 18326600)

Mumme and Stonehouse's 2015 meta-analysis (13 RCTs, n=749) compared MCTs (C8/C10 specifically) to LCTs on weight and composition outcomes:

• Body weight: -0.51 kg (95% CI -0.80 to -0.23, p<0.001)
• Waist circumference: -1.46 cm (95% CI -2.04 to -0.87, p<0.001)
• Hip circumference: -0.79 cm (95% CI -1.27 to -0.30, p=0.002)
• Visceral fat, subcutaneous fat, and total body fat all significantly reduced
• No significant difference in LDL, HDL, or total cholesterol [2]

The RCT by St-Onge and Bosarge (2008) enrolled 49 overweight adults (BMI ~30) in a 16-week parallel-arm trial comparing 18-24 g/day MCT oil vs. olive oil within an identical calorie-restricted diet. Of 31 completers, the MCT group showed significantly lower endpoint body weight (-1.67 kg, p=0.013), trunk fat mass, total fat mass, and intraabdominal adipose tissue compared to olive oil. The study design — identical caloric restriction across groups — isolates the metabolic effect of MCT vs. LCT rather than any overall diet change [3].

Satiety and food intake (PMID 32212947)

Maher and Clegg (2020) reviewed 17 studies (291 participants) and conducted a meta-analysis on 11 that measured energy intake outcomes. They found a statistically significant moderate decrease in ad libitum energy intake with MCT versus LCT (mean effect size -0.444, 95% CI -0.808 to -0.080, p=0.017). Notably, this reduction in consumption was not accompanied by changes in subjective appetite ratings or circulating hunger hormones (PYY, GLP-1, ghrelin). The authors speculate that the mechanism may involve portal vein signaling rather than systemic hormone changes, but this remains to be confirmed [6].

Athletic performance (PMID 36096496)

Chapman-Lopez and Koh (2022) reviewed 18 studies examining MCT oil and endurance performance. The majority found no statistically significant effect on any performance metric: time to exhaustion, power output, respiratory exchange ratio, substrate oxidation, blood lactate, or glucose. Ketone levels reliably increased in studies providing MCTs before or during exercise — but this ketogenic response did not appear to spare glycogen or reduce carbohydrate dependence during moderate-to-high intensity exercise. The authors conclude that MCT oil "showed very little to no ergogenic effects" in healthy populations [5].

Antimicrobial effects (PMID 24328700)

Shilling et al. (2013) tested the inhibitory activity of virgin coconut oil and its component fatty acids against C. difficile in culture. Lauric acid (C12) was the most potent inhibitor; capric acid (C10) and caprylic acid (C8) showed dose-dependent inhibition at concentrations of 0.15-1.2% lipolyzed coconut oil. Whole (non-hydrolyzed) coconut oil did not inhibit C. difficile, suggesting the effect requires enzymatic liberation of free fatty acids — as occurs during digestion [4]. These findings are in-vitro only; no clinical trials have tested MCT oil directly for C. difficile infection. The antimicrobial data is best interpreted as mechanistic support for in-vivo gut effects rather than clinical evidence.

Overall evidence strength

The strongest evidence supports brain energy support (mechanistic + RCT data in MCI/AD) and modest weight/composition benefits (multiple RCTs, consistent meta-analyses). The satiety evidence is moderately strong. The antimicrobial and gut health evidence is mechanistically plausible but clinically untested. The athletic performance evidence is a notable null — the mechanism exists but the real-world effect does not appear to materialize in most study populations. MCT oil is well-tolerated up to approximately 30 g/day; gastrointestinal symptoms are the primary adverse effect and are dose-dependent and reversible.